Skip to main content

Table 4 Adverse events reported in at least 10% of patients in any treatment group.

From: Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

 

Abrupt (n= 40)

Gradual 1 (n= 39)

Gradual 2 (n= 42)

All treatments (n= 121)

Patients with any adverse event

73%

90 %

79%

80%

Insomnia

23%

13%

24%

20%

Anxiety

18%

13%

14%

15%

Sedation

5%

18%

12%

12%

Somnolence

10%

10%

10%

10%

Headache

3%

10%

7%

7%

Aggravated psychosis

13%

0

5

6%